An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on ...

Trump looks forward to such things, but he has made the situation quite complicated for the citizens of his country.

Eli Lilly also responded to the President's tariff warnings by investing $27 billion to construct four manufacturing ...

As biopharma players continue to parse out what the second Trump administration means for the industry, Pfizer CEO Albert ...

Revolving door is a VERY polite term for Patrizia Cavazzoni's moves. Then again, she has a 25-year history of picking Big Pharma over vulnerable patients. She'll fit right in with Scott Gottlieb.

Health experts have slammed the FDA as 'corrupt' and 'in bed with Big Pharma' after its former drug chief Dr Patrizia Cavazzoni left the agency to serve as chief medical officer of Pfizer.

Cavazzoni previously worked at Pfizer prior to joining the FDA in 2018 ... when President Biden nominated him for the same job. Califf eventually made ethics concessions to Warren to secure ...

Shares of Pfizer (NYSE:PFE) have delivered negative returns since I started covering the stock and the last four months have not been great either as it is down another 12% since my previous ...

Pa­trizia Cavaz­zoni, the FDA’s for­mer head of drug reg­u­la­tion, will be­come Pfiz­er’s new chief med­ical of­fi­cer, End­points News has learned.

Pfizer shares jumped 8.6 per cent in Monday's trade on BSE, logging an intraday high at Rs 4,448.35 per share. The stock gained after the company's board approved entering into a marketing and supply ...

At Pfizer, she will be an executive vice president and will report to Chris Boshoff, the company’s new chief scientific officer, who leads all research and development. Her job will include ...